Bleomycin in Treating Patients With Non-Hodgkin's Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

July 31, 1997

Primary Completion Date

August 31, 2001

Study Completion Date

December 31, 2002

Conditions
Lymphoma
Interventions
BIOLOGICAL

bleomycin sulfate

Patients receive bleomycin by continuous infusion for 72 hours every 3 weeks. Induction therapy consists of 3 cycles. Patients who achieve complete remission receive 2 more cycles. Patients with partial remission or stable disease may continue therapy until disease progression or unacceptable toxicity occurs.

Trial Locations (1)

44106-5065

Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Case Comprehensive Cancer Center

OTHER

NCT00003110 - Bleomycin in Treating Patients With Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter